DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
Dexcom shares sank more than 40% on Friday, their steepest decline ever. The company reported disappointing revenue on Thursday and lowered its full-year guidance. Executives blamed a restructuring of ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
DexCom (NASDAQ:DXCM) will release its earnings report on Thursday, May 1, 2025. Historically, the stock has exhibited significant volatility around its earnings announcements. Over the past five years ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results